Evotec Gets $25 Million From Bristol Myers Squibb Partnership
Provided by
Dow Jones
By Sarah Sloat
Evotec said it would receive a $25 million milestone payment from Bristol Myers Squibb following progress in its partnership with the U.S. company.
The payment will go toward further research on the companies' joint pipeline of advanced neuroscience programs, the Hamburg-based biotechnology company said.
The companies began a collaboration in 2016 to identify treatments for a range of neurodegenerative diseases where there is a significant unmet need for therapies that slow down or reverse disease progression.
Write to Sarah Sloat at sarah.sloat@wsj.com
(END) Dow Jones Newswires
August 08, 2024 05:40 ET (09:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
United States